Invivyd, Inc. · NASDAQ:IVVD
Invivyd — Adagio Therapeutics — Investor Presentation (September 2022)
27 slides from Invivyd's investor presentation, Sep 12, 2022
Slide 1: Transcending the limitations of the immune system
Investor Presentation September 2022 Transcending the limitations of the immune system Exhibit 99.3
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “
Slide 3: A Fresh Start: What's in the name?
A Fresh Start What’s in the name? New Company and Board leadership, aligned with shareholders Substantial drug development and industry expertise brought to bear Company rapidly deploying best-in-class technology with an evolved strategy New name, renewed energy, major promise Validated Platform Vir
Slide 4: Invivyd: Transcending the Limitations of the Immune System
Invivyd: Transcending the Limitations of the Immune System Engineered antibodies designed to protect humans from serious viral diseases, starting with COVID-19 Engineered antibodies To transcend the limits of naturally occurring immunity and provide superior protection from viral diseases Discovery
Slide 5: The Problem: The immune system lacks sufficient response to many respiratory viruses
The Problem The immune system lacks sufficient response to many respiratory viruses, including SARS-CoV-2 COVID-19 inflicts an unacceptable burden on humankind even with vaccines and therapeutics The human immune response to vaccination and infection has kept us alive but at continued risk Mucosal i
Slide 6: The Invivyd Solution
The Invivyd Solution An integrated discovery platform aiming to continuously yield high-quality antibodies designed for breadth, potency, and higher barrier to viral escape Unique capability to combat viral evolution through discovery platform Explore expanses of the antibody universe beyond the com
Slide 7: COVID-19 Prevention and Treatment Represents a $95 Billion Market in 2022
COVID-19 Prevention and Treatment Represents a $95 Billion Market in 2022 Vaccines $ 60B Antivirals $ 30B mAbs $ 5B Source: Data compiled from 2020-2022 revenues from company earnings calls; 2023-2025 forecasted revenues from Global Data report “COVID-19 Sector Forecast: H1 2022, Global Analyst Cons
Slide 8: Significant Need for Differentiated Approaches to Prevention and Treatment
Significant Need for Differentiated Approaches to Prevention and Treatment Large Prevention Market 54 million people in U.S. aged 65+1 20 million immunocompromised in U.S. with 11 million moderate to severe2 115 million adults in U.S. with comorbidities3 Potential PrEP* population of ~25 million acr
Slide 9: mAbs Providing Extended Protection Offer a Compelling Alternative
mAbs Providing Extended Protection Offer a Compelling Alternative for the Vulnerable or Unvaccinated ONLY 68% of U.S. adults fully vaccinated for coronavirus as of Sept. 20221; protection waning constantly ONLY 55% of people aged 50+ with a past COVID-19 vaccine said they’re very likely to get a fal
Slide 10: Discovery Platform Overview
Discovery Platform Overview Strategy designed to overcome the challenges of viral evolution Deeply mine human antibody repertoires induced following diverse SARS-CoV-2 exposures Pinpoint dominant sites on the viral spike protein targeted by human immune repertoire and map mutational escape routes; p
Slide 11: Ongoing Discovery Creates Continuous Flow of Pipeline Candidates
Ongoing Discovery Creates Continuous Flow of Pipeline Candidates with the Goal of Addressing Virus Evolution Stringent Selection Criteria High potency neutralization Breadth of coverage No polyreactivity Low viscosity Rare epitopes No sequence liabilities 100s of neutralizing mAbs not in common repe
Slide 12: Robust Pipeline of Engineered Antibodies for Treatment and Prevention of Viral Diseases
Robust Pipeline of Engineered Antibodies for Treatment and Prevention of Viral Diseases Investigational therapies are not approved for use by regulatory authorities. The safety and efficacy of pipeline candidates have not been established.
Slide 13: Invivyd Aims to Establish Best In Class Performance Across Five Key Disciplines
Invivyd Aims to Establish Best In Class Performance Across Five Key Disciplines Prediction of viral evolution and rational selection of privileged epitopes Candidate antibody discovery and engineering Efficient clinical development for multiple use cases and populations Flexible and highly efficient
Slide 14: Discovery and Engineering Platform to Address COVID-19
Discovery and Engineering Platform to Address COVID-19
Slide 15: The Beginning: Deep B Cell Mining Identifies Preliminary Binders
The Beginning: Deep B Cell Mining Identifies Preliminary Binders Continuous monitoring and mining of diverse immune repertoires generates optimal starting points for engineering antibody candidates IML4041 IML4042 IML4043 IML4044 IML4045 Pre-pandemic Ctrl WT/BA.1 RBD | PE WT/BA.1 RBD | AF633 Donor I
Slide 16: Invivyd Explores Vast Antibody Diversity to Identify Optimal Candidates
Invivyd Explores Vast Antibody Diversity to Identify Optimal, Complementary Candidates for Engineering Highly productive Omicron lineage campaign yielded multiple candidates for engineering optimization XX Million B Cells 452 RBD binders 273 cross-neutralizers 53 broad VOC binders 142 non-convergent
Slide 17: Unique Engineering Capability Allows Fine Tuning and Optimization
NNK Diversified Library (~10^7 variants) Adintrevimab Affinity maturation against VOCs VYD222 Parent (ADG20) Library 1 nM BA.1 S1 Representative FACS selections: 5 nM BA.2 RBD Unique Engineering Capability Allows for Fine Tuning and Optimization: the Recovery of Adintrevimab RBD, receptor binding do
Slide 18: Broad Neutralizing Activity Against Pre-Omicron VOCs and Omicron
Data Shows Broad Neutralizing Activity Against Pre-Omicron VOCs and Omicron (+sub-lineages) VYD224 VYD222 Two Candidates Selected from Multiple Promising mAbs Identified VOC, variant of concern
Slide 19: NVD200 for Prevention & Treatment of COVID-19
Our Scale Generates Rational Combinations: NVD200 for Prevention & Treatment of COVID-19 Robust Pipeline of Engineered Antibodies for Treatment and Prevention of Viral Diseases Combination of VYD222 and VYD224 Neutralizing activity against VOCs, and SARS 1 Designed for: High potency Lack of polyreac
Slide 20: Continuous and Repeatable Process Designed to Address Viral Evolution
Continuous and Repeatable Process Designed to Address Viral Evolution 1 Procure Blood 2 Isolate B Cells 3 Sort Binders 4 Clone & Express IgGs 5 Characterize Library 6 Select & Engineer
Slide 21: Next Steps and Milestones
INVIVYD Next Steps and Milestones
Slide 22: Vision and Execution
INVIVYD sion and Execution
Slide 23: Future Expansion
Future Expansion Diseases where we see limitations of the human immune system Potential annual impact of seasonal influenza1 41 million cases Vaccine efficacy ranges from 10-60%2 and wanes within ~3 months after vaccination3 Invivyd engineered antibodies have potential to provide broader, more lasti
Slide 24: Management Team with Track Record of Success
Management Team with Track Record of Success Dave Hering CEO & Director Jane Pritchett Henderson Chief Financial & Business Officer Jill Andersen Chief Legal Officer & Corporate Secretary Ellie Hershberger, Pharm.D. Chief Development Officer Becky Dabora, Ph.D. Chief Technology & Manufacturing Offic
Slide 25: Our Vision
Our Vision Engineered antibodies designed to protect humans from serious viral diseases, starting with COVID-19 Engineered antibodies To transcend the limits of naturally occurring immunity and provide superior protection from viral diseases Discovery platform Integrates evolutionary virology, predi
Slide 26: Thank You
THANK YOU
Slide 27: Corporate Strategy: Achieve Mission in COVID-19 and Expand Beyond
Use Invivyd’s best-in-class discovery platform to develop engineered antibodies to provide a strong and lasting immune response against many viruses that cause upper respiratory infections. Corporate Strategy Achieve Mission in COVID-19 and Expand Beyond Develop and commercialize engineered antibodi
Adagio Therapeutics — Investor Presentation (September 2022) on 6ix